Page 12 - Pharma Sector

Pharmaceutical growth cure lies in CDMOs' resilience to market ailments

They get growth Rx from outsourcing, with fewer Trump tariff side effects

Health ministry flags 47 drugs as 'not of standard quality' in February

The Central Drugs Laboratories in its monthly drug alert for February found 47 drug samples manufactured by various firms to be "not of standard quality (NSQ)", health ministry officials said on Friday. Further, the State Drugs Testing Laboratories have identified 56 drug samples as NSQ, they said. According to routine regulatory surveillance activity, the list of NSQ drugs is displayed on the Central Drugs Standard Control Organisation (CDSCO) portal every month. Identification of drug samples as NSQ is done based on the failure of the drug sample in one or the other specified quality parameters, the officials said. The failure is specific to the drug products of the batch tested by the government laboratory and it does not warrant any concerns about the other drug products available in the market, an official said. In February 2024, one drug sample from West Bengal was identified as spurious and made by unauthorised manufacturer using a brand name owned by another company. The .

Entvin AI raises Rs 5 crore in first funding round from Y Combinator

With this funding, Entvin plans to expand its artificial intelligence capabilities and accelerate customer acquisition

Centre disbursed Rs 14,020 crore for 10 sectors so far under PLI schemes

The government has disbursed Rs 14,020 crore under Production-Linked Incentive schemes for ten sectors, including electronics and pharma, since the launch of the support measure to boost domestic manufacturing, an official statement said on Saturday. In 2021, the government announced Production-Linked Incentive (PLI) schemes for 14 sectors like telecommunication, white goods, textiles, manufacturing of medical devices, automobiles, speciality steel, food products, high-efficiency solar PV modules, advanced chemistry cell batteries, drones, and pharma, with an outlay of Rs 1.97 lakh crore. "The incentive amount of around Rs 14,020 crore disbursed under PLI schemes for 10 sectors," the commerce and industry ministry said. These sectors are large-scale electronics manufacturing, IT hardware, bulk drugs, medical devices, pharmaceuticals, telecom and networking products, food processing, white goods, automobiles and auto components and drones. Individual cases have been approved over a

Piramal Pharma arm, Irish firm get UKMHRA approval for Neoatricon in UK

Piramal Critical Care, a part of Piramal Pharma, and Ireland-based BrePco Biopharma have received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a medication used in the treatment of low blood pressure and low heart rate in children. Piramal Critical Care (PCC) has secured the commercialisation rights for Neoatricon, the first paediatric strength solution for infusion of Dopamine Hydrochloride, for the EU, the UK, and Norway markets, Piramal Pharma said in a regulatory filing. PCC would be responsible for distributing Neoatricon in these regions, it added. Developed by BrePco Biopharma, Neoatricon is an age-appropriate, ready-to-use, sterile solution for infusion of Dopamine Hydrochloride. It is available in a concentration of 1.5mg/mL in a 30 mL vial and a higher strength containing 4.5mg/mL in a 50 mL vial. Currently, there are no approved Dopamine Hydrochloride formulations specifically indicated for use in neonates, infants, or ..

Eli Lilly launches blockbuster anti-obesity drug Mounjaro in India. Prices here

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what you need to know

Here's why Marksans Pharma share was buzzing in trade on March 20

The products will be manufactured at the Verna, Goa facility, and will be marketed & distributed in Australian markets through the Marksans Pharma's subsidiary Nova Pharmaceuticals Australasia Pty

Diarrhoea and viral infections spur sales of probiotics, shows data

Antidiarrheals and anti-flatulents have also grown in strong double digits - 36 per cent and 29 per cent, respectively

IIT-B startup HaystackAnalytics plans to take genome testing to EU, US

Srivastava says that in the next five years they need to invest another $40-50 million or so to build the business, and there are plans to take the infexn test to the US and Europe as well

IPA refutes US univ's report questioning quality of Indian-made generics

Industry insiders pointed out that since India accounts for nearly 50 per cent of the generic drugs exported to the US, the share of adverse events also would be higher on a proportionate basis

Glenmark launches Empagliflozin for diabetes in India under Glempa brand

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'?Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range ..

Emcure Pharmaceuticals share gains on foraying into daily supplements space

The uptick in the Emcure Pharmaceuticals share price came after the company announced its entry into the daily supplements space with the expansion of its Arth range

Funds under PRIP scheme likely to be sanctioned by August 2025: DoP

The department had last week sought expressions of interest from interested entities for project funding under the PRIP scheme

Healthcare clocked $30 billion investment in 2 years, says report

The report states that hospitals in India undertook M&A deals worth $6.74 billion and attracted $4.96 billion from private equity (PE) investors

Aveo Pharma suspects misuse of painkiller Tafrodol in importing countries

The company also clarified that the "stop production" order of Feb 24 was due to compliance issues under the Schedule M of the Drugs and Cosmetics Rules, 1945, and not due to the combination product

Govt invites proposals for funding under Pharma MedTech sector scheme

The Department of Pharmaceuticals has sought expressions of interest from interested entities for project funding under the PRIP scheme. The Promotion of Research and Innovation in Pharma MedTech sector (PRIP) scheme has been launched by the Department of Pharmaceuticals to transform India into a global powerhouse for R&D in the Pharma MedTech sector. The scheme was notified on August 17, 2023, with a total financial outlay of Rs 5,000 crore, of which Rs 4,250 crore is focused on accelerating investments in the R&D ecosystem within the sector. Department of Pharmaceuticals invites Expressions of Interest (EoI) from interested entities --proprietary firm or partnership firm or limited liability partnership, startups or a company /Group of companies registered in India for project funding under the PRIP scheme, it stated. "This EoI has been designed to provide you with an opportunity to co-shape India's journey towards becoming an R&D innovation hub, by soliciting your ...

Sun Pharma to acquire US based Checkpoint Therapeutics for $355 million

The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations

US tariffs to hit pharma sector, while auto industry impact remains minimal

Enhanced tariffs on pharma imports in the US can severely impact Indian drug manufacturers as it would lead to higher production costs, making shipments less competitive against products from other countries. Smaller drug firms operating on thin margins can face severe pressure potentially forcing consolidation or closure. The automobile sector, on the other hand, is expected to have a very minimal impact owing to the US being a small export market. Terming India as a very high tariff nation, US President Donald Trump has said that reciprocal tariffs on countries that impose levies on American goods will kick in on April 2. India currently levies around 10 per cent import duty on American drugs, while the US doesn't charge any import duty on Indian drugs. Shardul Amarchand Mangaldas & Co Partner Arvind Sharma said as of recent history, the US has been a net importer of pharmaceutical products to meet its domestic demand. "In the event the US decides to impose substantial tariffs

Biocon Biologics, Civica partner to expand Insulin Aspart access in the US

Biocon Biologics' own Insulin Aspart drug product for the US is currently under review by the US Food and Drug Administration (FDA)

Piramal Enterprises hit with nearly $172 million tax bill for pharma deal

A tax office in the state of Maharashtra has asked the financial services company to pay 18% Goods and Services Tax (GST) on the deal, the latter said in the filing